✦ LIBER ✦

983 LONG-TERM 5-ALPHA REDUCTASE INHIBITOR USE IS ASSOCIATED WITH ADVERSE CLINICO-PATHOLOGIC FEATURES OF PROSTATE CANCER

✍ Scribed by O'Brien, Daniel C.; Loeb, Stacy; McGuire, Barry B.; Hu, Qiaoyan; Catalona, William

Book ID: 122427893
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 166 KB
Volume: 185
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2011.02.1015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association of 5α-reductase inhibitor us

Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy

✍ Sung Kyu Hong; Jong Jin Oh; Sangchul Lee; Hak Min Lee; Seok-Soo Byun; Gheeyoung 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

357 ASSOCIATION OF 5α-REDUCTASE INHIBITO

357 ASSOCIATION OF 5α-REDUCTASE INHIBITOR USE AND PATHOLOGICAL FEATURES OF PROSTATE CANCER IN MEN UNDERGOING RADICAL PROSTATECTOMY

✍ Hong, Sung Kyu; Oh, Jong Jin; Lee, Sangchul; Lee, Byung Ki; Joo, Young Min; Jeon 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 117 KB

Low-Activity V89L Variant in SRD5A2 Is A

Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors

✍ Olivier Cussenot; Abdel-Rahmène Azzouzi; Nathalie Nicolaiew; Philippe Mangin; Lu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Editorial Comment on: Low-Activity V89L

Editorial Comment on: Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors

✍ Tommaso Prayer-Galetti 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Editorial Comment on: Low-Activity V89L

✍ Christiane Maier 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 101 KB